癌症干细胞标志物CD44在卵巢癌中的预后作用：一项荟萃分析。

The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis.

作者信息

Lin Jiaying, Ding Ding

机构信息

Department of Assisted Reproduction, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639 Zhizaoju Road, Shanghai, 200011 China.

Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, 419 Fangxie Road, Shanghai, 200011 China.

出版信息

Cancer Cell Int. 2017 Jan 5;17:8. doi: 10.1186/s12935-016-0376-4. eCollection 2017.

BACKGROUND

CD44 has recently been reported as a cancer stem cell marker in ovarian cancer. However, the clinicopathological and prognostic value of this marker in ovarian cancer remains controversial; Here, we aimed to investigate the correlation between CD44 expression and the clinicopathological features or survival of ovarian cancer patients.

METHODS

An extensive literature search in the PubMed, EMBASE, and Wanfang databases (up to June 1, 2016) was conducted to identify studies that assessed the clinical or prognostic significance of CD44 expression in ovarian cancer. A meta-analysis was then performed to clarify the association between CD44 expression and clinical outcomes of ovarian cancer patients.

RESULTS

A total of 18 publications consisting of 2161 patients were included for this meta-analysis. Our data reveal that CD44-positive expression in ovarian cancers were significantly associated with a high TMN stage (pooled OR = 2.11, 95% CI 1.26-3.53, P = 0.004) and poor 5-year overall survival (RR = 1.42, 95% CI 1.01-2.00, P = 0.05). However, CD44 expression was not associated with tumor grade, lymphatic metastasis, age of the patients, residual tumor size, response to chemotherapy, or ascites volume (P > 0.05).

CONCLUSION

Detection of CD44 may be an effective tool for pathological diagnosis and prognostic prediction of ovarian cancer patients in clinical applications.

背景

最近有报道称CD44是卵巢癌中的一种癌症干细胞标志物。然而，该标志物在卵巢癌中的临床病理及预后价值仍存在争议；在此，我们旨在研究CD44表达与卵巢癌患者临床病理特征或生存率之间的相关性。

方法

在PubMed、EMBASE和万方数据库中进行广泛的文献检索（截至2016年6月1日），以识别评估CD44表达在卵巢癌中的临床或预后意义的研究。然后进行荟萃分析，以阐明CD44表达与卵巢癌患者临床结局之间的关联。

结果

本荟萃分析共纳入18篇文献，涉及2161例患者。我们的数据显示，卵巢癌中CD44阳性表达与高TMN分期显著相关（合并OR = 2.11，95%CI 1.26 - 3.53，P = 0.004）以及5年总生存率较差（RR = 1.42，95%CI 1.01 - 2.00，P = 0.05）。然而，CD44表达与肿瘤分级、淋巴转移、患者年龄、残余肿瘤大小、化疗反应或腹水量无关（P > 0.05）。